Orion Oyj (HEL:ORNAV)
Finland · Delayed Price · Currency is EUR | Market Cap | 9.54B +34.4% |
| Revenue (ttm) | 1.95B +22.9% |
| Net Income | 529.40M +52.4% |
| EPS | 3.76 +52.1% |
| Shares Out | n/a |
| PE Ratio | 18.02 |
| Forward PE | 15.68 |
| Dividend | 1.80 (2.66%) |
| Ex-Dividend Date | Oct 19, 2026 |
| Volume | 3,550 |
| Average Volume | 10,127 |
| Open | 69.50 |
| Previous Close | 67.60 |
| Day's Range | 66.40 - 69.50 |
| 52-Week Range | 51.60 - 75.10 |
| Beta | 0.30 |
| RSI | 36.70 |
| Earnings Date | Apr 23, 2026 |
About Orion Oyj
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti... [Read more]
Financial Performance
In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.
Financial StatementsNews
Orion Oyj (ORINF) Q1 2026 Earnings Call Highlights: Robust Growth and Strategic Outlook
Orion Oyj (ORINF) Q1 2026 Earnings Call Highlights: Robust Growth and Strategic Outlook
Q1 2026 Orion Oyj Earnings Call Transcript
Q1 2026 Orion Oyj Earnings Call Transcript
Orion Oyj Earnings Call Transcript: Q1 2026
Q1 2026 saw strong growth across all divisions, with net sales up 18% and operating profit up 47% year-over-year. Upgraded full-year guidance reflects robust performance, especially in Innovative Medicines, and reduced downside risk from US tariffs.
Orion Oyj Earnings Call Transcript: Q4 2025
Record 2025 results driven by Nubeqa milestone, strong growth across all divisions, and robust R&D progress. 2026 guidance anticipates higher sales, profit, and continued investment in pipeline and capacity. Dividend of €1.80 per share proposed.
Orion Oyj Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong growth is driven by innovative oncology medicines, especially Nubeqa, with robust financial targets through 2028. Expansion into the US and Asia-Pacific, a diversified pipeline, and a flexible dividend policy support long-term global ambitions.
Orion Oyj Earnings Call Transcript: Q3 2025
Nubeqa drove record royalties and strong growth in innovative medicines, while generics and consumer health also performed well. Guidance was narrowed as year-end visibility improved, with R&D and U.S. pricing remaining key uncertainties.
Orion Oyj Earnings Call Transcript: Q2 2025
Q2 2025 saw strong growth across all divisions, with net sales up 27% and operating profit up 59%, driven by innovative medicines and Nubeqa royalties. Updated guidance reflects continued momentum but maintains a wide range due to uncertainties in royalties, R&D timing, and market factors.
Orion Oyj Transcript: CMD 2025
Achieved key financial targets ahead of schedule and set ambitious growth plans through geographic expansion, portfolio transformation, and increased R&D investment. Focus areas include innovative medicines, branded products, generics, and animal health, with robust financial discipline and readiness for strategic acquisitions.
Orion Oyj Earnings Call Transcript: Q1 2025
Q1 2025 saw 15% net sales and 39% operating profit growth, led by innovative medicines and strong Nubeqa sales. Guidance for the year remains unchanged, with ongoing R&D expansion and a new phase III project for Levosimendan.
Orion Oyj Earnings Call Transcript: Q4 2024
2024 saw nearly 30% sales growth, driven by Nubeqa and milestone payments, with strong cash flow and a 33% rise in operating profit. 2025 guidance reflects Nubeqa's growing impact, wider ranges due to R&D and FX uncertainty, and no major milestones expected. Nubeqa now represents 34% of revenue.
Orion Oyj Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Strong growth is driven by geographic expansion, innovative oncology products, and a diversified portfolio. Nubeqa has reached blockbuster status, and the pipeline includes promising oncology and insomnia drugs. Financial targets through 2028 emphasize sustained growth and shareholder returns.
Orion Oyj Earnings Call Transcript: Q3 2024
Q3 saw robust growth, boosted by EUR 130 million in milestone payments and strong sales from Nubeqa, Easyhaler, and Animal Health. Despite project terminations and write-downs, guidance for 2024 remains unchanged, with R&D resources shifting to new oncology and biologics projects.
Orion Oyj Earnings Call Transcript: Q2 2024
Q2 and H1 2024 delivered strong growth in net sales and operating profit, led by Nubeqa and Easyhaler, with improved cash flow and upgraded full-year guidance. Key milestones include a major MSD license deal and positive Nubeqa phase 3 results.